Sanofi-Aventis has room for sales force reductions: Spek

Share this article:

Sanofi-Aventis has the flexibility to further reduce its sales force, the drugmaker's head of pharmaceuticals Hanspeter Spek said during a post-results conference call on Wednesday.

“I don't believe our overall sales force will increase – there will be inside restructuring,” Spek told Reuters.

Spek said around 10% of the US sales force typically leaves each year and another 10% are external hires.

Sanofi has already cut its US sales force by 11% since 2005.

Meanwhile, Sanofi reported that second quarter sales of its sleeping pill Ambien fell 42%. The Paris-based drugmaker was counting on weight-loss drug Acomplia to boost company growth but had to withdraw the drug last month after an FDA expert panel linked it to suicide and depression.

“They're not in good shape,” Eric le Berrigaud, an analyst at Raymond James in Paris, told Reuters. “Their portfolio is pretty old now, they really need new products.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...